bioAffinity Technologies, Inc. (NASDAQ:BIAF) Sees Large Decrease in Short Interest

bioAffinity Technologies, Inc. (NASDAQ:BIAF) was the recipient of a large decrease in short interest during the month of January. As of January 15th, there was short interest totaling 40,326 shares, a decrease of 22.4% from the December 31st total of 51,967 shares. Currently, 0.9% of the shares of the company are sold short. Based on an average daily trading volume, of 73,792 shares, the days-to-cover ratio is currently 0.5 days. Based on an average daily trading volume, of 73,792 shares, the days-to-cover ratio is currently 0.5 days. Currently, 0.9% of the shares of the company are sold short.

Analysts Set New Price Targets

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of bioAffinity Technologies in a report on Wednesday, January 21st. One research analyst has rated the stock with a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Reduce”.

Institutional Investors Weigh In On bioAffinity Technologies

A hedge fund recently bought a new stake in bioAffinity Technologies stock. Scientech Research LLC purchased a new stake in shares of bioAffinity Technologies, Inc. (NASDAQ:BIAF) in the third quarter, according to its most recent disclosure with the SEC. The firm purchased 16,583 shares of the company’s stock, valued at approximately $49,000. Scientech Research LLC owned approximately 0.46% of bioAffinity Technologies as of its most recent filing with the SEC. Institutional investors and hedge funds own 1.64% of the company’s stock.

bioAffinity Technologies Stock Performance

BIAF stock traded down $0.03 during trading on Friday, reaching $1.14. 53,502 shares of the company’s stock were exchanged, compared to its average volume of 61,808. The firm has a market cap of $5.13 million, a PE ratio of -0.05 and a beta of 2.45. The company has a quick ratio of 3.64, a current ratio of 3.65 and a debt-to-equity ratio of 0.01. bioAffinity Technologies has a 1-year low of $1.11 and a 1-year high of $46.53. The company’s fifty day moving average price is $1.36 and its 200-day moving average price is $4.09.

bioAffinity Technologies (NASDAQ:BIAF) last posted its quarterly earnings data on Friday, November 14th. The company reported ($2.70) earnings per share for the quarter, hitting the consensus estimate of ($2.70). The business had revenue of $1.45 million during the quarter, compared to the consensus estimate of $1.41 million. bioAffinity Technologies had a negative net margin of 217.45% and a negative return on equity of 425.87%.

bioAffinity Technologies Company Profile

bioAffinity Technologies, Inc (NASDAQ: BIAF) is a U.S.-based biotechnology company specializing in the development and commercialization of advanced in vitro diagnostic platforms for oncology. Leveraging proprietary bioaffinity and nanotechnology approaches, bioAffinity’s platforms are designed to isolate and analyze cancer-specific biomarkers from blood, tissue, and other biological samples with high sensitivity and specificity. The company’s core technologies aim to enable earlier detection of solid tumors, improved disease monitoring, and more personalized treatment strategies.

The company’s primary product pipeline includes assays targeting breast cancer and other solid tumor indications.